News

April 19, 2017

Tecentriq Granted Accelerated Approval for Certain Advanced Bladder Cancer Patients

News

Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for Platinol (cisplatin) treatment will now have access to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) in the ... Read more

April 18, 2017

Opdivo Fails to Demonstrate Survival Benefit in Phase 3 Brain Cancer Trial

News

Patients with glioblastoma multiforme, a type of brain cancer, who recurred following radiation therapy and Temodal (temozolomide), did not survive longer when treated with the PD-1 inhibitor Opdivo (nivolumab) compared to standard-of-care ... Read more

April 17, 2017April 17, 2017

Oncolytics Working on Reolysin Immunotherapy Applications After Good Breast Cancer Results

News

Oncolytics Biotech is partnering with other companies to develop immunotherapy and immunomodulatory applications for Reolysin, which improved breast cancer survival rates. A combination of Reolysin and the chemotherapy Taxol (paclitaxel) increased ... Read more

April 13, 2017

Bayer Ends Partnership with OncoMed on Compounds That Inhibit Cancer Stem Cell Pathways

News

Bayer Pharma has decided not to exercise its option to license two cancer stem cell pathway inhibitors from OncoMed, effectively ending their partnership in this area. OncoMed developed the first-in-class ... Read more

April 12, 2017April 12, 2017

FDA Grants Orphan Drug Designation to NantCell’s Ganitumab to Treat Ewing Sarcoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan-drug status to Ganitumab, a human monoclonal antibody with anti-cancer properties, to treat patients with Ewing sarcoma. The decision was welcomed by Patrick Soon-Shiong, ... Read more

April 11, 2017April 11, 2017

SY-1425 May Work in Combo with Approved Therapies in Leukemia Patients, Others with Blood Disorders

News

Preclinical data on SY-1425, Syros Pharmaceuticals’ selective retinoic acid receptor alpha (RARα) agonist, suggest this is a promising treatment to be used in combination with Vidaza (azaciditine), a standard of ... Read more

April 10, 2017

First Patient Dosed in Phase 1 Trial of Individualized Cancer Vaccine AutoSynVax

News

Agenus has dosed the first patient in a Phase 1 trial evaluating the cancer vaccine AutoSynVax (ASV) for advanced cancer. Preclinical-trial data, presented at the American Association for Cancer Research ... Read more

April 7, 2017April 7, 2017

Immunotherapy, OSE-172, Seen to Be Safe and Effective in Mouse Models of Liver Cancer

News

OSE-172, an immune checkpoint inhibitor that blocks immunosupressive cells in the tumor microenvironment, was shown to be safe in tumor mouse models and to induce strong remission rates when used in ... Read more

April 6, 2017

Novartis Gets Closer to FDA Approval of Its CTL019 Therapy for Certain Leukemia Patients

News

Novartis is a step closer to the U.S. Food and Drug Administration approving its CAR T-cell therapy CTL019 for certain patients with leukemia. The FDA has accepted Novartis’ Biologics License Application for CTL109. ... Read more

April 5, 2017

Fred Hutchinson Researchers Present New Findings on Cancer Immunotherapy

News

Researchers from the Fred Hutchinson Cancer Research Center talked about recent developments and new research findings in immunotherapy at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention ... Read more